A prospective, observational study to evaluate effectiveness and safety of fixed dose combination of Indacaterol maleate 110 mcg and Glycopyrronium bromide 50 mcg in stable Chronic Obstructive Pulmonary Disease (COPD) patients - Ultibro Study
Phase of Trial: Phase IV
Latest Information Update: 30 Dec 2017
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms Ultibro
- Sponsors Novartis
- 15 Dec 2017 Planned number of patients changed from 1000 to 428.
- 06 Feb 2017 Status changed from not yet recruiting to recruiting.
- 13 Dec 2016 New trial record